DAJY(SZ:002030)2022-12-08 08:18Group 1: Company Partnerships - The company has established a joint venture with Life Technologies, focusing on the development of sequencing reagents, with Life Technologies providing sequencing equipment [1][2] - The collaboration with Guangzhou Zhongda Holdings aims to integrate medical resources from Sun Yat-sen University, enhancing social benefits and optimizing existing assets [2][3] Group 2: Financial Status - The company currently has no financing needs, with normal operational conditions and no issues regarding bank credit or equity pledges [3] - The company is not facing any funding shortages [3] Group 3: Support and Governance - Sun Yat-sen University is the actual controller of the company but does not interfere in daily management, which operates under a well-structured market-oriented governance model [3] - The company is positioned above average among listed companies affiliated with universities in terms of marketization [3] Group 4: Future Development - The company focuses on molecular diagnostic technology and does not rule out future expansion into therapeutic areas, while currently prioritizing the integration of the diagnostic industry chain [4] - The stock option incentive plan was confirmed and filed with the regulatory authority, with plans to submit it for board and shareholder approval [4]